PURPOSE: To determine whether corneal graft survival over a 5-year follow-up period was affected by ABO blood type compatibility in participants in the Cornea Donor Study undergoing corneal transplantation principally for Fuchs dystrophy or pseudophakic corneal edema, conditions at low-risk for graft rejection. DESIGN: Multi-center prospective, double-masked, clinical trial. METHODS: ABO blood group compatibility was determined for 1,002 donors and recipients. During a 5-year follow-up period, episodes of graft rejection were documented, and graft failures were classified as to whether or not they were attributable to immunologic rejection. Endothelial cell density was determined by a central reading center for a subset of subjects. RESULTS: ABO donor-recipient incompatibility was not associated with graft failure attributable to any cause including graft failure because of rejection, or with the occurrence of a rejection episode. The 5-year cumulative incidence of graft failure attributable to rejection was 32 (6%) for recipients with ABO recipient-donor compatibility and 12 (4%) for those with ABO incompatibility (hazard ratio, 0.65; 95% confidence interval, 0.33 to 1.25; P = .20). The 5-year incidence for a definite rejection episode, irrespective of whether graft failure ultimately occurred, was 64 (12%) for ABO compatible compared with 25 (8%) for ABO incompatible cases (P = .09). Among clear grafts at 5 years, percent loss of endothelial cells was similar in ABO compatible and incompatible cases. CONCLUSIONS: In patients undergoing penetrating keratoplasty for Fuchs dystrophy or pseudophakic corneal edema, ABO matching is not indicated since ABO incompatibility does not increase the risk of transplant failure attributable to graft rejection.
RCT Entities:
PURPOSE: To determine whether corneal graft survival over a 5-year follow-up period was affected by ABO blood type compatibility in participants in the Cornea Donor Study undergoing corneal transplantation principally for Fuchs dystrophy or pseudophakic corneal edema, conditions at low-risk for graft rejection. DESIGN: Multi-center prospective, double-masked, clinical trial. METHODS:ABO blood group compatibility was determined for 1,002 donors and recipients. During a 5-year follow-up period, episodes of graft rejection were documented, and graft failures were classified as to whether or not they were attributable to immunologic rejection. Endothelial cell density was determined by a central reading center for a subset of subjects. RESULTS:ABOdonor-recipient incompatibility was not associated with graft failure attributable to any cause including graft failure because of rejection, or with the occurrence of a rejection episode. The 5-year cumulative incidence of graft failure attributable to rejection was 32 (6%) for recipients with ABO recipient-donor compatibility and 12 (4%) for those with ABO incompatibility (hazard ratio, 0.65; 95% confidence interval, 0.33 to 1.25; P = .20). The 5-year incidence for a definite rejection episode, irrespective of whether graft failure ultimately occurred, was 64 (12%) for ABO compatible compared with 25 (8%) for ABO incompatible cases (P = .09). Among clear grafts at 5 years, percent loss of endothelial cells was similar in ABO compatible and incompatible cases. CONCLUSIONS: In patients undergoing penetrating keratoplasty for Fuchs dystrophy or pseudophakic corneal edema, ABO matching is not indicated since ABO incompatibility does not increase the risk of transplant failure attributable to graft rejection.
Authors: Robin L gal; Mariya Dontchev; Roy W Beck; Mark J Mannis; Edward J Holland; Craig Kollman; Steven P Dunn; Ellen L Heck; Jonathan H Lass; Monty M Montoya; Robert L Schultze; R Doyle Stulting; Alan Sugar; Joel Sugar; Bradley Tennant; David D Verdier Journal: Ophthalmology Date: 2008-04 Impact factor: 12.079
Authors: Jonathan H Lass; Robin L Gal; Mariya Dontchev; Roy W Beck; Craig Kollman; Steven P Dunn; Ellen Heck; Edward J Holland; Mark J Mannis; Monty M Montoya; Robert L Schultze; R Doyle Stulting; Alan Sugar; Joel Sugar; Bradley Tennant; David D Verdier Journal: Ophthalmology Date: 2008-04 Impact factor: 12.079
Authors: Steven P Dunn; Robin L Gal; Craig Kollman; Dan Raghinaru; Mariya Dontchev; Christopher L Blanton; Edward J Holland; Jonathan H Lass; Kenneth R Kenyon; Mark J Mannis; Shahzad I Mian; Christopher J Rapuano; Walter J Stark; Roy W Beck Journal: Cornea Date: 2014-10 Impact factor: 2.651
Authors: Jonathan H Lass; Roy W Beck; Beth Ann Benetz; Mariya Dontchev; Robin L Gal; Edward J Holland; Craig Kollman; Mark J Mannis; Francis Price; Irving Raber; Walter Stark; R Doyle Stulting; Alan Sugar Journal: Arch Ophthalmol Date: 2011-05-09
Authors: R Doyle Stulting; Alan Sugar; Roy Beck; Michael Belin; Mariya Dontchev; Robert S Feder; Robin L Gal; Edward J Holland; Craig Kollman; Mark J Mannis; Francis Price; Walter Stark; David D Verdier Journal: Cornea Date: 2012-10 Impact factor: 2.651
Authors: Alan Sugar; Robin L Gal; Craig Kollman; Dan Raghinaru; Mariya Dontchev; Christopher R Croasdale; Robert S Feder; Edward J Holland; Jonathan H Lass; Jonathan I Macy; Mark J Mannis; Patricia W Smith; Sarkis H Soukiasian; Roy W Beck Journal: JAMA Ophthalmol Date: 2015-03 Impact factor: 7.389
Authors: Beth Ann Benetz; Jonathan H Lass; Robin L Gal; Alan Sugar; Harry Menegay; Mariya Dontchev; Craig Kollman; Roy W Beck; Mark J Mannis; Edward J Holland; Mark Gorovoy; Sadeer B Hannush; John E Bokosky; James W Caudill Journal: JAMA Ophthalmol Date: 2013-05 Impact factor: 7.389